PROGNOSTIC VALUE OF CYP1A2 (rs2069514 AND rs762551) POLYMORPHISMS IN COVID-19 PATIENTS
Bozkurt I, Gözler T, Yüksel I, Ulucan K, Tarhan KN
*Corresponding Author: Prof.Dr. Korkut Ulucan, Saray, Site Yolu Cd No:27, Umraniye/ Istanbul, Turkey, 34768, email: korkutulucan@hotmail.com.tr; +902164002222
page: 35
|
|
REFERENCES
1. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C.
Q., & He, J. X. (2019). & Zhong, NS (2020). Clinical
characteristics of coronavirus disease, 1708-1720.
2. Wu, Y., Ho, W., Huang, Y., Jin, D. Y., Li, S., Liu,
S. L., ... & Zheng, Z. M. (2020). SARS-CoV-2 is
an appropriate name for the new coronavirus. The
Lancet, 395(10228), 949-950.
3. Cucinotta, D., & Vanelli, M. (2020). WHO declares
COVID-19 a pandemic. Acta bio medica: Atenei parmensis,
91(1), 157.
4. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song,
J., ... & Tan, W. (2020). A novel coronavirus from patients
with pneumonia in China, 2019. New England
journal of medicine.
5. Bedford, J., Enria, D., Giesecke, J., Heymann, D.
L., Ihekweazu, C., Kobinger, G., ... & Wieler, L. H.
(2020). WHO Strategic and Technical Advisory Group
for Infectious Hazards. COVID-19: towards controlling
of a pandemic. Lancet, 395(10229), 1015-1018.
6. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu,
Y., ... & Cao, B. (2020). Clinical features of patients
infected with 2019 novel coronavirus in Wuhan,
China. The lancet, 395(10223), 497-506.
7. Mehta, P., McAuley, D. F., Brown, M., Sanchez, E.,
Tattersall, R. S., & Manson, J. J. (2020). COVID-19:
consider cytokine storm syndromes and immunosuppression.
The lancet, 395(10229), 1033-1034.
8. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., &
Ng, L. F. (2020). The trinity of COVID-19: immunity,
inflammation and intervention. Nature Reviews Immunology,
20(6), 363-374.
9. Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020).
Severe COVID-19. New England Journal of Medicine,
383(25), 2451-2460.
10. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ...
& Cao, B. (2020). Clinical course and risk factors
for mortality of adult inpatients with COVID-19 in
Wuhan, China: a retrospective cohort study. The lancet,
395(10229), 1054-1062.
11. Tobin, M. J., Laghi, F., & Jubran, A. (2020). Why
COVID-19 silent hypoxemia is baffling to physicians.
American journal of respiratory and critical
care medicine, 202(3), 356-360.
12. Liu, Y., Lv, J., Liu, J., Li, M., Xie, J., Lv, Q., ... &
Huang, B. (2020). Mucus production stimulated
by IFN-AhR signaling triggers hypoxia of COVID-
19. Cell Research, 30(12), 1078-1087.
13. Sanders, J. M., Monogue, M. L., Jodlowski, T. Z.,
& Cutrell, J. B. (2020). Pharmacologic treatments
for coronavirus disease 2019 (COVID-19): a review.
Jama, 323(18), 1824-1836.
14. Almazroo, O. A., Miah, M. K., & Venkataramanan,
R. (2017). Drug metabolism in the liver. Clinics in
liver disease, 21(1), 1-20.
15. Wang, K., Zuo, P., Liu, Y., Zhang, M., Zhao, X., Xie, S.,
... & Liu, C. (2020). Clinical and laboratory predictors
of in-hospital mortality in patients with coronavirus
disease-2019: a cohort study in Wuhan, China. Clinical
infectious diseases, 71(16), 2079-2088.
16. Ramos-Lopez, O., Daimiel, L., Ramírez de Molina,
A., Martínez-Urbistondo, D., Vargas, J. A., &
Martínez, J. A. (2020). Exploring host genetic polymorphisms
involved in SARS-CoV infection outcomes:
Implications for personalized medicine in
COVID-19. International journal of genomics, 2020.
17. Keyvani, H., Zahednasab, H., Sholeh, M., Mirzaei,
R., Esghaei, M., & Karampoor, S. (2020). Gender
Preponderance Might be Associated with the Severity
of COVID-19 Infection. J Clin Cell Immunol, 11, 598.
18. Karampoor, S., Afrashteh, F., & Laali, A. (2021).
Persistent hiccups after treatment of COVID-19 with
dexamethasone: A case report. Respiratory Medicine
Case Reports, 34, 101515.
19. Hill, A. V. (2012). Evolution, revolution and heresy
in the genetics of infectious disease susceptibility.
Philosophical Transactions of the Royal Society
B: Biological Sciences, 367(1590), 840-849.
20. Patarčić, I., Gelemanović, A., Kirin, M., Kolčić, I.,
Theodoratou, E., Baillie, K. J., ... & Polašek, O. (2015).
The role of host genetic factors in respiratory tract
infectious diseases: systematic review, meta-analyses
and field synopsis. Scientific reports, 5(1), 16119.
21. Yucesoy, B., Kapici, S., Sercan, C., Yigitbasi, T., Emekli,
N., & Ulucan, K. (2017). Determination of the
Distribution of the rs2069514 and rs762551 Alleles
of the Cyp1a2 Gene Related to Caffeine Metabolism
in Professional Athletes. European Journal of Biology,
76(2), 69-73.
22. Pijls, B. G., Jolani, S., Atherley, A., Dijkstra, J. I.,
Franssen, G. H., Hendriks, S., ... & Zeegers, M. P.
(2022). Temporal trends of sex differences for COVID-
19 infection, hospitalisation, severe disease,
intensive care unit (ICU) admission and death: a
meta-analysis of 229 studies covering over 10M patients.
F1000Research, 11.
23. Cohen, J. F., Korevaar, D. A., Matczak, S., Chalumeau,
M., Allali, S., & Toubiana, J. (2021). COVID-19–related
fatalities and intensive-care-unit admissions by
age groups in Europe: a meta-analysis. Frontiers in
Medicine, 7, 560685.
24. Teker, A. G., Emecen, A. N., Girgin, S., Şimşek-
Keskin, H., Şiyve, N., Sezgin, E., ... & Ünal, B. (2021).
Türkiye’de Bir Üniversite Hastanesinde COVID-19
Olgularının Epidemiyolojik Özellikleri. Klimik Journal/
Klimik Dergisi, 34(1).
25. Jain, V., & Yuan, J. M. (2020). Predictive symptoms
and comorbidities for severe COVID-19 and
intensive care unit admission: a systematic review
and meta-analysis. International journal of public
health, 65, 533-546.
26. Yamamoto, N., Ariumi, Y., Nishida, N., Yamamoto,
R., Bauer, G., Gojobori, T., ... & Mizokami, M.
(2020). SARS-CoV-2 infections and COVID-19
mortalities strongly correlate with ACE1 I/D genotype.
Gene, 758, 144944.
27. Gómez, J., Albaiceta, G. M., García-Clemente, M.,
López-Larrea, C., Amado-Rodríguez, L., Lopez-
Alonso, I., ... & Coto, E. (2020). Angiotensin-converting
enzymes (ACE, ACE2) gene variants and
COVID-19 outcome. Gene, 762, 145102.
28. Pinheiro, D. S., Santos, R. S., Jardim, P. C. V., Silva,
E. G., Reis, A. A., Pedrino, G. R., & Ulhoa, C. J.
(2019). The combination of ACE I/D and ACE2
G8790A polymorphisms revels susceptibility to hypertension:
A genetic association study in Brazilian
patients. PloS one, 14(8), e0221248.
29. Lenoir, C., Terrier, J., Gloor, Y., Curtin, F., Rollason,
V., Desmeules, J. A., ... & Samer, C. F. (2021). Impact
of SARS‐CoV‐2 infection (COVID‐19) on cytochromes
P450 activity assessed by the Geneva cocktail.
Clinical Pharmacology & Therapeutics, 110(5),
1358-1367.
30. Kar, N., Barreto, S., & Chandavarkar, R. (2016). Clozapine
monitoring in clinical practice: beyond the
mandatory requirement. Clinical Psychopharmacology
and Neuroscience, 14(4), 323.
31. de Leon, J. (2004). Respiratory infections rather than
antibiotics may increase clozapine levels: a critical
review of the literature. The Journal of clinical psychiatry,
65(8), 18148.
32. Dotson, S., Hartvigsen, N., Wesner, T., Carbary, T. J.,
Fricchione, G., & Freudenreich, O. (2020). Clozapine
toxicity in the setting of COVID-19. Psychosomatics,
61(5), 577.
33. DiAngelo, Z., Berlin, J., Wang, S., Gutowski, B., &
Bahnsen, R. (2022). (32) Clozapine Toxicity Following
COVID-19 Infection: A Case Series. Journal of
the Academy of Consultation-liaison Psychiatry, 63,
S128-S128.
34. Reis, G., dos Santos Moreira-Silva, E. A., Silva, D.
C. M., Thabane, L., Milagres, A. C., Ferreira, T. S.,
... & Mills, E. J. (2022). Effect of early treatment
with fluvoxamine on risk of emergency care and
hospitalisation among patients with COVID-19: the
TOGETHER randomised, platform clinical trial. The
Lancet Global Health, 10(1), e42-e51.
35. Tio, N., Schulte, P. F., & Martens, H. J. (2021). Clozapine
intoxication in COVID-19. American Journal
of Psychiatry, 178(2), 123-127.
36. Elfaki, I. (2022). The Impact of the Coronavirus
(COVID-19) Infection on the Drug-Metabolizing
Enzymes Cytochrome P450s. Drug Metabolism and
Bioanalysis Letters Formerly: Drug Metabolism Letters,
15(2), 71-74.
37. Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R.
B. (2012). PharmGKB summary: very important
pharmacogene information for CYP1A2. Pharmacogenetics
and genomics, 22(1), 73.
38. Rahman, M. S., & Thomas, P. (2018). Interactive effects
of hypoxia and PCB co‐exposure on expression of
CYP1A and its potential regulators in Atlantic croaker
liver. Environmental toxicology, 33(4), 411-421.
|
|
|
